Glioblastoma
The most common length of survival following diagnosis is 12 to 15 months, with fewer than 3% to 5% of people surviving longer than five years. Without treatment survival is typically 3 months.
Glioblastoma
Antiangiogenic therapy with medications such as bevacizumab control symptoms but do not affect overall survival.